Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
2015 | journal article???letter_note???. A publication with affiliation to the University of Göttingen.
Jump to:Cite & Linked | Documents & Media | Details | Version history
Documents & Media
Details
- Authors
- Zeisberg, Michael ; Zeisberg, Elisabeth M.
- Abstract
- Among gliptins, linagliptin is unique, because decreased glomerular filtration rate does not require dose reduction. Linagliptin was originally developed to lower blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4). However, DPP-4 has numerous additional substrates, and thus gliptins possess a vast range of additional off-target effects. Shi et al. report that linagliptin directly targets interaction of DPP-4 with integrin beta 1, preventing endothelial-mesenchymal transition and ultimately renal fibrosis, providing additional rationale for use of linagliptin in diabetic nephropathy.
- Issue Date
- 2015
- Status
- published
- Publisher
- Nature Publishing Group
- Journal
- Kidney International
- ISSN
- 1523-1755; 0085-2538